DNA Damage and Specificity of a New Anti-Cancer Agent
Author Information
Author(s): M. Broggini, J.A. Hartley, W.B. Mattes, M. Ponti, K.W. Kohn, M. D'Incalci
Primary Institution: Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; National Cancer Institute, NIH, Bethesda, MD, USA
Hypothesis
What is the DNA damage and sequence specificity of the new anti-cancer agent Dabis maleate?
Conclusion
Dabis maleate causes DNA interstrand cross-links and cell cycle arrest in L1210 cells without producing DNA single strand breaks.
Supporting Evidence
- Dabis maleate and Dabis analogue were found to be cytotoxic in vitro.
- Both compounds caused an arrest of L1210 cells in G2/M phase of the cell cycle.
- Dabis maleate alkylates guanine at the N7-position with differences in specificity compared to other alkylating agents.
- Moderate DNA interstrand cross-links were detected in L1210 cells treated with both compounds.
Takeaway
Dabis maleate is a new cancer drug that can damage DNA and stop cancer cells from growing, but it works differently than some other drugs.
Methodology
L1210 cells were treated with Dabis maleate and Dabis analogue to evaluate cytotoxicity and DNA damage using various assays.
Limitations
The study does not provide information on long-term effects or in vivo results.
Participant Demographics
L1210 leukaemia cells were used in the study.
Want to read the original?
Access the complete publication on the publisher's website